sodium channel associated protein 2 |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type III, beta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type I, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type III, beta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type I, beta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type II, beta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
CLEMASTINE |
Calcium Channel Type L, Benzothiazepine |
78% |
2.241uM |
1.992uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
CLEMASTINE |
Calcium Channel Type L, Benzothiazepine |
78% |
2.241uM |
1.992uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
CLEMASTINE |
Calcium Channel Type L, Benzothiazepine |
78% |
2.241uM |
1.992uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CLEMASTINE |
Calcium Channel Type L, Benzothiazepine |
78% |
2.241uM |
1.992uM |
View
|
androgen receptor |
GENTIAN VIOLET |
Testosterone |
78% |
5.57uM |
3.713uM |
View
|
thromboxane A synthase 1 |
GENISTEIN |
Thromboxane Synthetase |
78% |
7.72uM |
NoneNone |
View
|
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
GENISTEIN |
Thromboxane Synthetase |
78% |
7.72uM |
NoneNone |
View
|
acetylcholinesterase (YT blood group) |
GENTIAN VIOLET |
Acetylcholinesterase |
78% |
5.847uM |
NoneNone |
View
|
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
GENTIAN VIOLET |
Acetylcholinesterase |
78% |
5.847uM |
NoneNone |
View
|
acetylcholinesterase |
GENTIAN VIOLET |
Acetylcholinesterase |
78% |
5.847uM |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
BROMOCRIPTINE |
Sodium Channel, Site 2 |
78% |
6.692uM |
6.105uM |
View
|
sodium channel associated protein 1 |
BROMOCRIPTINE |
Sodium Channel, Site 2 |
78% |
6.692uM |
6.105uM |
View
|
sodium channel associated protein 2 |
BROMOCRIPTINE |
Sodium Channel, Site 2 |
78% |
6.692uM |
6.105uM |
View
|
sodium channel, voltage-gated, type III, beta |
BROMOCRIPTINE |
Sodium Channel, Site 2 |
78% |
6.692uM |
6.105uM |
View
|
sodium channel, voltage-gated, type I, alpha |
BROMOCRIPTINE |
Sodium Channel, Site 2 |
78% |
6.692uM |
6.105uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
BENZTROPINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
1.348uM |
1.311uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
SPIRADOLINE |
Calcium Channel Type L, Phenylalkylamine |
78% |
5.24uM |
5.095uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PROMAZINE |
Calcium Channel Type L, Benzothiazepine |
77% |
3.217uM |
2.86uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type I, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type II, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type X, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IV, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type III, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type II, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type I, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IV, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel associated protein 1 |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel associated protein 2 |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type III, beta |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
PROMAZINE |
Sodium Channel, Site 2 |
77% |
2.573uM |
2.347uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
PAROXETINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.747uM |
.726uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
PAROXETINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.747uM |
.726uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PAROXETINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.747uM |
.726uM |
View
|
carbonic anhydrase 5a, mitochondrial |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase 3 |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase 2 |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase 4 |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase XI |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase IX |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase VIII |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase VII |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase VA, mitochondrial |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase IV |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase III, muscle specific |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase I |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase XIV |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase VB, mitochondrial |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase XII |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase VI |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
carbonic anhydrase II |
ROSIGLITAZONE |
Carbonic Anhydrase |
76% |
4.069uM |
NoneNone |
View
|
adrenergic receptor, alpha 1b |
PROPAFENONE |
Adrenergic alpha1B |
76% |
2.558uM |
1.416uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PENTAMIDINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
1.391uM |
1.352uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
PERGOLIDE |
Calcium Channel Type L, Phenylalkylamine |
76% |
.913uM |
.887uM |
View
|
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
BW-723C86 |
Dopamine Transporter |
76% |
2.6846uM |
2.133uM |
View
|
dopamine receptor D3 |
TRANS-PLATINUM(II)DIAMMINE DICHLORIDE |
Dopamine D3 |
76% |
3.3237uM |
1.1288uM |
View
|
cholinergic receptor, muscarinic 3 |
PERHEXILINE |
Muscarinic M3 |
76% |
3.1186uM |
.661uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type X, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
DOXORUBICIN |
Sodium Channel, Site 2 |
75% |
15.245uM |
13.668uM |
View
|
5-hydroxytryptamine receptor 6 |
AMLODIPINE |
Serotonin 5-HT6 |
75% |
2.898uM |
1.346uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
LOVASTATIN |
Adrenergic, Norepinephrine Transporter |
75% |
8.753uM |
8.68uM |
View
|
opioid receptor, delta 1 |
AMIODARONE |
Opiate delta |
75% |
8.014uM |
2.825uM |
View
|
5-hydroxytryptamine (serotonin) receptor 3a |
CHLORPROMAZINE |
Serotonin 5-HT3 |
75% |
7.365uM |
1.655uM |
View
|
5-hydroxytryptamine (serotonin) receptor 3b |
CHLORPROMAZINE |
Serotonin 5-HT3 |
75% |
7.365uM |
1.655uM |
View
|
aldo-keto reductase family 1, member B4 (aldose reductase) |
ZOMEPIRAC |
Aldose Reductase |
75% |
1.29uM |
NoneNone |
View
|
aldo-keto reductase family 1, member B1 (aldose reductase) |
ZOMEPIRAC |
Aldose Reductase |
75% |
1.29uM |
NoneNone |
View
|
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
ZOMEPIRAC |
Aldose Reductase |
75% |
1.29uM |
NoneNone |
View
|
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
ZOMEPIRAC |
Aldose Reductase |
75% |
1.29uM |
NoneNone |
View
|
melanocortin 5 receptor |
TAMOXIFEN |
Melanocortin MC5 |
75% |
26.529uM |
24.886uM |
View
|
bradykinin receptor, beta 2 |
TAMOXIFEN |
Bradykinin B2 |
75% |
20.356uM |
12.048uM |
View
|
bradykinin receptor B2 |
TAMOXIFEN |
Bradykinin B2 |
75% |
20.356uM |
12.048uM |
View
|
progesterone receptor |
TAMOXIFEN |
Progesterone |
75% |
19.846uM |
2.589uM |
View
|
progesterone receptor |
TAMOXIFEN |
Progesterone |
75% |
19.846uM |
2.589uM |
View
|
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
THIMEROSAL |
Serotonin Transporter |
75% |
2.015uM |
1.07uM |
View
|
phosphodiesterase 5A, cGMP-specific |
DIPYRIDAMOLE |
Phosphodiesterase PDE5 |
75% |
2.831uM |
NoneNone |
View
|
phosphodiesterase 5A, cGMP-specific |
DIPYRIDAMOLE |
Phosphodiesterase PDE5 |
75% |
2.831uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
IPRIFLAVONE |
Cyclooxygenase COX-1 |
75% |
2.9443uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
IPRIFLAVONE |
Cyclooxygenase COX-1 |
75% |
2.9443uM |
NoneNone |
View
|
aldo-keto reductase family 1, member B4 (aldose reductase) |
DICUMAROL |
Aldose Reductase |
75% |
4.093uM |
NoneNone |
View
|
aldo-keto reductase family 1, member B1 (aldose reductase) |
DICUMAROL |
Aldose Reductase |
75% |
4.093uM |
NoneNone |
View
|
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
DICUMAROL |
Aldose Reductase |
75% |
4.093uM |
NoneNone |
View
|
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
DICUMAROL |
Aldose Reductase |
75% |
4.093uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
TOLNAFTATE |
Serotonin 5-HT2B |
75% |
2.007uM |
1.277uM |
View
|
adrenergic receptor, alpha 2b |
MOSAPRIDE |
Adrenergic alpha2B |
75% |
1.908uM |
.871uM |
View
|
mitogen activated protein kinase 14 |
ISOTRETINOIN |
Protein Serine/Threonine Kinase, p38alpha |
75% |
2.529uM |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
ISOTRETINOIN |
Protein Serine/Threonine Kinase, p38alpha |
75% |
2.529uM |
NoneNone |
View
|